APRE Aprea Therapeutics Forecast, Technical & Fundamental Analysis
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers... Show more
APRE is expected to report earnings to fall 14.77% to -18 cents per share on August 06
Q2'26
Est.
$-0.19
Q1'26
Missed
by $0.10
Q4'25
Missed
by $0.01
Q3'25
Missed
by $0.19
Q2'25
Missed
by $0.27
The last earnings report on May 13 showed earnings per share of -21 cents, missing the estimate of -11 cents. With 61.97K shares outstanding, the current market capitalization sits at 8.65M.
A.I.dvisor tells us that APRE and ATOS have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that APRE and ATOS's prices will move in lockstep.
APRE in upward trend: price may ascend as a result of having broken its lower Bollinger Band on June 02, 2026
APRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 45 cases where APRE's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where APRE advanced for three days, in of 210 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on May 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on APRE as a result. In of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for APRE turned negative on May 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .
APRE moved below its 50-day moving average on June 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for APRE crossed bearishly below the 50-day moving average on June 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where APRE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for APRE entered a downward trend on June 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.208) is normal, around the industry mean (18.816). P/E Ratio (0.000) is within average values for comparable stocks, (36.093). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.681). APRE has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.039). P/S Ratio (0.000) is also within normal values, averaging (359.668).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. APRE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
